Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. 1994

P F Lin, and H Samanta, and R E Rose, and A K Patick, and J Trimble, and C M Bechtold, and D R Revie, and N C Khan, and M E Federici, and H Li
Department of Virology and Antiviral Clinical Research, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492.

Development of stavudine resistance was studied using human immunodeficiency virus type 1 isolates from 13 patients treated with stavudine for 18-22 months. Drug sensitivity testing on 11 of these pre- and posttherapy isolates identified only 2 posttreatment isolates with decreased stavudine sensitivity (ED50s < 4-fold higher than the average pretreatment ED50). Genotypic analysis of all 13 pairs of isolates identified multiple mutations in the reverse transcriptase (RT) gene. However, no genetic basis was identified to account for the observed changes in stavudine susceptibility. A recombinant virus containing the entire RT gene of the posttherapy isolate displaying the greatest resistance remained sensitive to stavudine. Five of the stavudine posttreatment isolates developed resistance (9- to 176-fold) to zidovudine, although the relationship between stavudine treatment and the appearance of zidovudine resistance remains unexplained. Analysis of 10 additional pairs of isolates did not confirm this relationship. The low frequency and modest degree of change in stavudine sensitivity following prolonged treatment is very encouraging.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D018119 Stavudine A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. 2',3'-Didehydro-3'-deoxythymidine,D4T,2',3'-Didehydro-2',3'-dideoxythmidine,BMY-27857,Stavudine, Monosodium Salt,Zerit,2',3' Didehydro 3' deoxythymidine,BMY 27857,BMY27857

Related Publications

P F Lin, and H Samanta, and R E Rose, and A K Patick, and J Trimble, and C M Bechtold, and D R Revie, and N C Khan, and M E Federici, and H Li
September 2001, The Journal of infectious diseases,
P F Lin, and H Samanta, and R E Rose, and A K Patick, and J Trimble, and C M Bechtold, and D R Revie, and N C Khan, and M E Federici, and H Li
July 1998, Antimicrobial agents and chemotherapy,
P F Lin, and H Samanta, and R E Rose, and A K Patick, and J Trimble, and C M Bechtold, and D R Revie, and N C Khan, and M E Federici, and H Li
December 2002, Antimicrobial agents and chemotherapy,
P F Lin, and H Samanta, and R E Rose, and A K Patick, and J Trimble, and C M Bechtold, and D R Revie, and N C Khan, and M E Federici, and H Li
January 2008, Archives of virology,
P F Lin, and H Samanta, and R E Rose, and A K Patick, and J Trimble, and C M Bechtold, and D R Revie, and N C Khan, and M E Federici, and H Li
December 2002, Journal of clinical microbiology,
P F Lin, and H Samanta, and R E Rose, and A K Patick, and J Trimble, and C M Bechtold, and D R Revie, and N C Khan, and M E Federici, and H Li
August 1995, Journal of virology,
P F Lin, and H Samanta, and R E Rose, and A K Patick, and J Trimble, and C M Bechtold, and D R Revie, and N C Khan, and M E Federici, and H Li
January 2006, AIDS research and human retroviruses,
P F Lin, and H Samanta, and R E Rose, and A K Patick, and J Trimble, and C M Bechtold, and D R Revie, and N C Khan, and M E Federici, and H Li
November 1997, Journal of virology,
P F Lin, and H Samanta, and R E Rose, and A K Patick, and J Trimble, and C M Bechtold, and D R Revie, and N C Khan, and M E Federici, and H Li
January 2002, AIDS research and human retroviruses,
P F Lin, and H Samanta, and R E Rose, and A K Patick, and J Trimble, and C M Bechtold, and D R Revie, and N C Khan, and M E Federici, and H Li
May 1999, AIDS research and human retroviruses,
Copied contents to your clipboard!